High-dose vitamin C safety for pyruvate kinase or G6PD deficiency
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests whether high doses of vitamin C are safe for people with certain red blood cell conditions: pyruvate kinase deficiency or a specific type of G6PD deficiency (Class A). The goal is to see if vitamin C can be given safely to these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of pyruvate kinase deficiency or a specific type of G6PD deficiency (Class A).
- You must be 18 years old or older.
- You must be able to take oral medications, either by mouth or through a feeding tube.
- You must be willing to give written consent to participate.
- For the G6PD group: women who carry the gene for Class A G6PD deficiency are eligible.
- You cannot be pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a medicine called Glycerol Phenylbutyrate (RAVICTI) is safe and helpful for children and young adults with a specific type of PDH deficiency, a rare genetic condition affecting energy use. If you qualify, you may get a new treatment option.
This trial provides access to an investigational drug called DCA (dichloroacetate) for people with pyruvate dehydrogenase complex deficiency, a rare genetic condition that affects energy production in the body. The goal is to offer a possible treatment option for those who have few other choices.
This Phase 3 study tests an oral form of vitamin B6 (P5P) to treat PNPO deficiency, a rare genetic condition that can cause seizures. It’s meant for people whose seizures are usually controlled on this treatment, to confirm the best approach going forward.
This study tests whether giving high-dose vitamin C can help improve kidney function in people with severe liver failure, sudden kidney injury, and a serious infection with very low blood pressure. It's a randomized trial, meaning half the participants get vitamin C and half get a placebo, to see which group does better.
This trial tests adding high-dose vitamin C (ascorbate) to the standard two-drug treatment (azacitidine and venetoclax) for people with newly diagnosed acute myeloid leukemia who are not candidates for intensive chemo. The goal is to see if the vitamin C makes the standard treatment work better and helps control the leukemia.
This trial tests a special high-dose vitamin C infusion, given based on how your body processes it, for people with advanced solid tumors. It aims to see if this vitamin C therapy can be safely combined with your current or new chemotherapy to help control the cancer.
Hear when a new Pyruvate Kinase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.